Company intelligence / Profile preview
Avobis Bio
Newark, Delaware, United Statesavobisbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Phase II clinical trial (STOMP-II) for AVB-114 has completed enrollment at 14 US sites. Primary endpoint results are expected in mid-2025. The therapy received FDA Fast Track designation in February 2025.
- Therapeutic areas
- Gastroenterology
- Modalities
- Implantable cell therapiesMesenchymal stem cell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
VinetiPNC Bank
Beyond the preview
Go deeper on Avobis Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avobis Bio.